132-22-9 Usage
Chemical Properties
BP
Uses
Chlorpheniramine is a drug in the class of first-generation
antihistamines, used to help alleviate symptoms of allergic
reactions potentiated by histamine release. Though it is
included in many multisymptom over-the-counter cold relief
medications, the Food and Drug Administration (FDA) issued
a safety alert in March 2011 detailing some risks associated
with these medications. The safety alert also indicated that
increased enforcement of FDA laws governing the marketing
of these drugs would occur, as many of the products had not
been approved in their current formulations for safety, effectiveness,
and quality.
Chlorpheniramine is commonly used in small-animal
veterinary medicine for its antihistaminic/antipruritic effects,
especially for the treatment of pruritus in cats, and occasionally
as a mild sedative.
Environmental Fate
Toxicity of antihistamines is usually related to their anticholinergic
effects and may include loss of appetite, nausea,
vomiting, diarrhea or constipation, and other GI effects, as well
as dizziness, tinnitus, lassitude, incoordination, fatigue, blurred
vision, diplopia, euphoria, nervousness, insomnia, and
tremors. Acetylcholine is competitively blocked at muscarinic
receptors, resulting in symptoms of anticholinergic poisoning.
Concurrent use of alcohol, tricyclic antidepressants, monoamine
oxidase inhibitors, or other central nervous system
(CNS) depressants along with antihistamines may exaggerate
and extend the anticholinergic and CNS depressant effects of
antihistamines; concurrent use is not recommended.
Products that were marketed prior to the FDA safety alert
but not approved by the FDA included multisymptom cold
medications comprised of drug combinations of chlorpheniramine
with decongestants, antitussives, and analgesics. Risks
associated with the use of these products included improper
use in children and infants, potentially risky combination of
ingredients, and patients receiving too much or too little
medication because of problems with the way some ‘extendedrelease’
products were made. Newborn and premature infants
are even more prone to anticholinergic side effects and an
increased susceptibility toward convulsions; thus, this drug is
not recommended at all in this age group. Geriatric patients are
also more prone to anticholinergic effects, and a paradoxical
reaction characterized by hyperexcitability may occur in some
children taking antihistamines. Overdosage may also produce
central excitation resulting in convulsions.
Check Digit Verification of cas no
The CAS Registry Mumber 132-22-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,3 and 2 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 132-22:
(5*1)+(4*3)+(3*2)+(2*2)+(1*2)=29
29 % 10 = 9
So 132-22-9 is a valid CAS Registry Number.
InChI:InChI=1/C16H19ClN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-8,10,12,16H,9,11H2,1-2H3
132-22-9Relevant articles and documents
Mass fragmentographic determination of d and l chlorpheniramine with aid of the stable isotope technique
Miyazaki,Abuki
, p. 2572 - 2574 (1976)
-
Novel synthetic method for chlorpheniramine maleate
-
, (2017/07/19)
The invention belongs to the field of medicinal chemistry, and specifically relates to a synthetic method for chlorphenamine maleate. The method provided by the invention comprises the following steps in sequence: (1) allowing p-cyanobenzylchloride to react with acetylene under the catalysis of a catalyst namely cobaltocene so as to generate p-chlorobenzyl pyridine; and (2) allowing p-chlorobenzyl pyridine to react with N,N-dimethyl chloroethane under the catalysis of sodium amide so as to generate chlorpheniramine, and subjecting chlorpheniramine and maleic acid to a neutralization reaction so as to generate chlorpheniramine maleate.
New synthetic route to N,N-disubstituted 3-aryl-3-pyridylpropylamines: Pheniramines from 3-aryl-3-(2-pyridyl)propanals
Marchetti, Mauro,Sechi, Barbara,Azzena, Ugo,Botteghi, Carlo,Paganelli, Stefano,Ponte, Gino Del,Stefani, Helio A.
, p. 219 - 225 (2007/10/03)
3-Aryl-3-(2-pyridyl)propanals 3, useful precursors compound for the H1 antihistaminic agents Pheniramines 1 were prepared following three different reaction pathways: the first one involves the rhodium catalyzed regiospecific hydroformylation of cinnamaldehyde acetals 4; the second one was carried out through the hydro-hydroxyacetamidation reaction on 1-aryl-1-(2-pyridyl)ethenes 2 followed by oxidative cleavage of the intermediate α-hydroxybutanamides 10; the third one was accomplished through alkylation of 2-benzylpyridines 12 with 2-bromomethyl-1,3-dioxolane 13 using LDA as deprotonating agent. The last preparative route showed to be the most convenient giving Pheniramine 1 up to 80 percent overall yield.